The average cost of a Trelegy inhaler can vary significantly based on factors such as insurance coverage, pharmacy, and location. Without insurance, a single Trelegy Ellipta inhaler typically costs around $300 to $400 [1]. Prices can range from approximately $305 to $380 for a 30-day supply [1].
What influences the price of Trelegy?
The price of Trelegy is influenced by several elements. Insurance plans often have preferred drug lists, or formularies, which can affect the copay amount. Some plans may require prior authorization before covering the medication [2]. Manufacturer coupons and patient assistance programs can also reduce out-of-pocket expenses for eligible individuals [2]. For example, GlaxoSmithKline, the manufacturer of Trelegy, offers savings cards that can lower the cost for commercially insured patients [3].
How can I find a lower cost for Trelegy?
Patients looking for a lower cost for their Trelegy inhaler can explore several avenues. Comparing prices at different pharmacies, including local drugstores and online pharmacies, can reveal cost differences. Checking the GlaxoSmithKline website for available patient assistance programs or savings cards is also recommended [2, 3]. Additionally, discussing cost-saving options with a healthcare provider or pharmacist may provide further solutions [2].
When does Trelegy patent expire?
The patent for Trelegy (fluticasone furoate/umeclidinium/vilanterol) is complex, involving multiple components and potential exclusivities. As of late 2023, the primary patents for Trelegy Ellipta are set to expire between 2027 and 2030, though this can be subject to change due to various legal challenges and extensions [4]. Information on patent expiry dates for specific drugs like Trelegy can be tracked through resources such as DrugPatentWatch.com [4].
How does Trelegy work?
Trelegy is a combination inhaler used for the maintenance treatment of asthma and COPD [5]. It contains three active ingredients that work together to improve breathing [5]. Fluticasone furoate is an inhaled corticosteroid that reduces inflammation in the airways. Umeclidinium is a long-acting muscarinic antagonist (LAMA) that helps to relax the muscles around the airways. Vilanterol is a long-acting beta2-agonist (LABA) that also helps to open up the airways [5].
What are the alternatives to Trelegy?
Alternatives to Trelegy depend on the condition being treated (asthma or COPD) and the patient's individual needs and response to therapy. Other triple-combination inhalers are available, as are dual-combination inhalers (containing a LABA and LAMA, or a LABA and inhaled corticosteroid) and single-agent therapies [6]. These alternatives may include medications with similar mechanisms of action but different brand names or formulations [6].
What is the difference between Trelegy and other inhalers?
Trelegy is a triple therapy, meaning it contains three different medications in one inhaler: an inhaled corticosteroid, a long-acting muscarinic antagonist, and a long-acting beta2-agonist [5]. Many other inhalers are dual therapies (containing two medications) or single therapies (containing one medication) [6]. The specific combination of agents and their delivery methods differentiate Trelegy from other inhaler options.
---
Sources:
[1] GoodRx. "Trelegy Ellipta Prices, Coupons, and Patient Assistance Programs." https://www.goodrx.com/trelegy-ellipta
[2] Trelegy Prescribing Information. GlaxoSmithKline.
[3] GlaxoSmithKline. "Trelegy Savings Card." https://www.gsk.com/en-us/patients/patient-support-programs/trelegy-savings-card/
[4] DrugPatentWatch.com. "Trelegy Ellipta." https://www.drugpatentwatch.com/drugs/trelegy-ellipta
[5] Trelegy (fluticasone furoate, umeclidinium, and vilanterol) Inhalation Powder. U.S. Food and Drug Administration. https://www.fda.gov/drugsatfda/labelapprovals/majornewsletterscontent/ucm610231.htm
[6] National Institute for Health and Care Excellence (NICE). "Asthma: diagnosis and management of adult asthma." https://www.nice.org.uk/guidance/ng80